ANCHOR

Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).
An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.

• Experimental : Experimental ECMO + IABP Arm
  VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.
  An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible).
• No Intervention: Control Conventional Treatment Arm
  Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.